Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the Jefferies Global Healthcare Conference on November 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company develops transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel Prize-winning science of RNAi, achieving critical breakthroughs and bringing six medicines to approval. Its medicines are available in more than 70 countries, supported by a robust and rapidly expanding pipeline, and the Company is consistently recognized as an exceptional workplace and a socially responsible organization. Alnylam is executing its Alnylam 2030 strategy to accelerate innovation and scale its impact on human health. For more information, visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104554718/en/
Alnylam Pharmaceuticals, Inc.
Bo Piela
(Media)
508-308-9783
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.